X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-02-03 | HQL | Abrdn Life Sciences Investors | Saba Capital Management, L.P. | 10% | S - Sale | $14.04 | -5,911 | 3,375,460 | 0% | -$83,013 | |||||
| D | 2025-02-04 | ACCD | Accolade, Inc. | Barnes Stephen H. | CFO | S - Sale+OE | $6.93 | -448 | 301,364 | 0% | -$3,103 | |||||
| D | 2025-02-04 | ACCD | Accolade, Inc. | Cavanaugh Robert N | Pres | S - Sale+OE | $6.93 | -557 | 216,100 | 0% | -$3,858 | |||||
2025-02-03 | VZ | Verizon Communications Inc | Malady Kyle | EVP, Group CEO-VZ Business | S - Sale | $39.89 | -8,000 | 25,005 | -24% | -$319,080 | ||||||
| D | 2025-02-04 | ACCD | Accolade, Inc. | Singh Rajeev | CEO | S - Sale+OE | $6.93 | -1,170 | 1,474,446 | 0% | -$8,103 | |||||
| D | 2025-02-04 | ACCD | Accolade, Inc. | Eskew Richard | EVP GC | S - Sale+OE | $6.93 | -390 | 64,016 | -1% | -$2,701 | |||||
| M | 2025-02-03 | NXJ | Nuveen New Jersey Quality Municipal Income Fund | Saba Capital Management, L.P. | 10% | S - Sale | $12.14 | -46,139 | 4,788,978 | -1% | -$560,039 | |||||
| M | 2025-02-03 | BCAT | Blackrock Capital Allocation Term Trust | Saba Capital Management, L.P. | 10% | S - Sale | $15.50 | -60,380 | 13,341,862 | 0% | -$935,735 | |||||
2025-02-04 | BXP | Bxp, Inc. | Spann Hilary J. | EVP | S - Sale | $72.02 | -12,379 | 7,271 | -63% | -$891,536 | ||||||
| M | 2025-02-03 | MPA | Blackrock Muniyield Pennsylvania Quality Fund | Saba Capital Management, L.P. | 10% | S - Sale | $11.87 | -14,406 | 2,166,300 | -1% | -$170,999 | |||||
2025-02-03 | HURN | Huron Consulting Group Inc. | Lockhart H Eugene | Dir | S - Sale | $125.15 | -1,042 | 24,672 | -4% | -$130,406 | ||||||
| M | 2025-02-03 | BFZ | Blackrock California Municipal Income Trust | Saba Capital Management, L.P. | 10% | S - Sale | $11.29 | -53,560 | 4,923,631 | -1% | -$604,692 | |||||
2025-02-03 | HURN | Huron Consulting Group Inc. | McCartney John | Dir | S - Sale | $125.15 | -500 | 56,188 | -1% | -$62,575 | ||||||
2025-02-03 | MAV | Pioneer Municipal High Income Advantage Fund, Inc. | Saba Capital Management, L.P. | 10% | P - Purchase | $8.54 | +1,215 | 3,922,889 | 0% | +$10,376 | ||||||
2025-02-04 | ISSC | Innovative Solutions & Support Inc | Harborne Christopher | 10% | S - Sale | $11.21 | -63,368 | 2,311,615 | -3% | -$710,495 | ||||||
| M | 2025-02-03 | PKBK | Parke Bancorp, Inc. | Kripitz Jeffrey H | Dir | S - Sale | $20.19 | -7,559 | 235,759 | -3% | -$152,620 | |||||
2025-02-03 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale | $53.81 | -10,000 | 311,147 | -3% | -$538,061 | ||||||
2025-02-03 | FDBC | Fidelity D & D Bancorp Inc | Vilcek Helenbeth Garofalo | Dir | P - Purchase | $0.00 | +4,500 | 162,984 | +3% | +$0 | ||||||
| M | 2025-01-31 | TKO | Tko Group Holdings, Inc. | Whitesell Patrick | 10% | P - Purchase | $157.27 | +251,506 | 3,748,325 | +7% | +$39,553,775 | |||||
| M | 2025-01-31 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $176.85 | -43,902 | 70,629 | -38% | -$7,763,862 | |||||
| M | 2025-01-31 | TKO | Tko Group Holdings, Inc. | Emanuel Ariel | CEO, 10% | P - Purchase | $157.27 | +251,506 | 3,748,325 | +7% | +$39,553,775 | |||||
| M | 2025-01-31 | NYC | American Strategic Investment Co. | Schorsch Nicholas S | 10% | P - Purchase | $10.39 | +4,405 | 1,503,473 | 0% | +$45,783 | |||||
| M | 2025-01-31 | TKO | Tko Group Holdings, Inc. | Silver Lake West Holdco, L.P. | 10% | P - Purchase | $157.27 | +251,506 | 3,682,146 | +7% | +$39,553,775 | |||||
| D | 2025-02-04 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale+OE | $59.43 | -1,678 | 101,186 | -2% | -$99,724 | |||||
| D | 2025-02-04 | RYTM | Rhythm Pharmaceuticals, Inc. | Shulman Joseph | Chief Technical Officer | S - Sale+OE | $59.43 | -1,281 | 2,657 | -33% | -$76,130 | |||||
| D | 2025-02-04 | RYTM | Rhythm Pharmaceuticals, Inc. | Meeker David P | Pres, CEO | S - Sale+OE | $59.43 | -4,278 | 189,927 | -2% | -$254,242 | |||||
| D | 2025-02-04 | RYTM | Rhythm Pharmaceuticals, Inc. | Lee Jennifer Kayden | EVP, Head of North America | S - Sale+OE | $59.43 | -1,447 | 4,038 | -26% | -$85,995 | |||||
| D | 2025-02-04 | RYTM | Rhythm Pharmaceuticals, Inc. | Cramer Pamela J. | CHRO | S - Sale+OE | $59.43 | -902 | 15,248 | -6% | -$53,606 | |||||
| D | 2025-02-04 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $64.57 | -1,500 | 0 | -100% | -$96,855 | |||||
| D | 2025-02-03 | EVGO | Evgo Inc. | Kish Dennis G | Pres | S - Sale+OE | $3.41 | -44,184 | 95,986 | -32% | -$150,557 | |||||
| AD | 2025-01-03 | EVGO | Evgo Inc. | Kish Dennis G | Pres | S - Sale+OE | $4.32 | -17,379 | 61,269 | -22% | -$75,015 | |||||
2025-02-04 | WM | Waste Management Inc | Hemmer Tara J. | SVP, Chief Sustainability Off | S - Sale | $222.12 | -4,576 | 58,765 | -7% | -$1,016,421 | ||||||
2025-02-04 | WM | Waste Management Inc | Rankin Devina A | EVP, CFO | S - Sale | $222.12 | -5,826 | 69,442 | -8% | -$1,294,071 | ||||||
2025-02-03 | EA | Electronic Arts Inc. | Singh Vijayanthimala | Chief People Officer | S - Sale | $122.03 | -1,000 | 28,216 | -3% | -$122,030 | ||||||
| D | 2025-02-03 | TVTX | Travere Therapeutics, Inc. | Rote William E. | SVP, R, D | S - Sale+OE | $19.78 | -8,951 | 95,719 | -9% | -$177,051 | |||||
| D | 2025-02-03 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | SVP, GC, Corporate Secretary | S - Sale+OE | $19.78 | -8,951 | 89,482 | -9% | -$177,051 | |||||
| D | 2025-02-03 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO | S - Sale+OE | $20.21 | -50,691 | 430,548 | -11% | -$1,024,343 | |||||
| DM | 2025-02-03 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Chief Medical Officer | S - Sale+OE | $20.12 | -5,273 | 84,170 | -6% | -$106,082 | |||||
| D | 2025-02-03 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Chief Commercial Officer | S - Sale+OE | $20.12 | -5,166 | 122,708 | -4% | -$103,940 | |||||
| D | 2025-02-03 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale+OE | $20.12 | -5,192 | 90,038 | -5% | -$104,463 | |||||
| D | 2025-02-03 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, Chief Accounting Officer | S - Sale+OE | $20.12 | -3,348 | 63,654 | -5% | -$67,362 | |||||
| D | 2025-02-03 | NFLX | Netflix Inc | Mather Ann | Dir | S - Sale+OE | $973.00 | -2,682 | 0 | -100% | -$2,609,586 | |||||
| D | 2025-02-03 | NFLX | Netflix Inc | Hastings Reed | Exec COB | S - Sale+OE | $978.39 | -32,067 | 2,154,590 | -1% | -$31,373,997 | |||||
2025-02-03 | TRU | Transunion | Chaouki Steven M | Pres, US Markets | S - Sale | $95.95 | -1,000 | 58,488 | -2% | -$95,950 | ||||||
2025-02-03 | GWRE | Guidewire Software, Inc. | Mullen John P | Pres | S - Sale | $208.79 | -3,000 | 174,746 | -2% | -$626,366 | ||||||
2025-02-03 | GWRE | Guidewire Software, Inc. | Rosenbaum Michael George | CEO | S - Sale | $208.42 | -1,400 | 276,130 | -1% | -$291,788 | ||||||
2025-02-03 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $12.70 | -8,338 | 178,692 | -4% | -$105,893 | ||||||
2025-02-03 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd Franklin | See Remarks | S - Sale | $12.70 | -19,301 | 1,035,269 | -2% | -$245,123 | ||||||
2025-02-03 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $12.71 | -10,000 | 141,944 | -7% | -$127,100 | ||||||
2025-02-03 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale | $12.70 | -12,116 | 114,862 | -10% | -$153,873 | ||||||
2025-02-03 | ARQT | Arcutis Biotherapeutics, Inc. | Edwards Larry Todd | See Remarks | S - Sale | $12.70 | -2,173 | 135,555 | -2% | -$27,597 | ||||||
| D | 2025-02-03 | RSI | Rush Street Interactive, Inc. | Roosileht Einar | CIO | S - Sale+OE | $14.41 | -70,000 | 3,620,307 | -2% | -$1,008,434 | |||||
| D | 2025-01-31 | RDDT | Reddit, Inc. | Huffman Steve Ladd | CEO, Pres, 10% | S - Sale+OE | $201.97 | -14,000 | 614,394 | -2% | -$2,827,506 | |||||
| M | 2025-02-03 | RSI | Rush Street Interactive, Inc. | Stetz Mattias | COO | S - Sale | $14.50 | -30,000 | 761,537 | -4% | -$435,113 | |||||
| D | 2025-01-29 | DMAA | Drugs Made In America Acquisition Corp. | Drugs Made In America Acquisition LLC | 10% | P - Purchase | $0.00 | +400,000 | 4,158,780 | +11% | +$0 | |||||
| D | 2025-01-29 | DMAA | Drugs Made In America Acquisition Corp. | Drugs Made In America Acquisition LLC | 10% | S - Sale+OE | $0.00 | -5,698,363 | 4,158,780 | -58% | -$0 | |||||
| D | 2025-01-29 | DMAA | Drugs Made In America Acquisition Corp. | Stockwell Lynn | CEO, Exec COB, 10% | P - Purchase | $0.00 | +400,000 | 4,158,780 | +11% | +$0 | |||||
| D | 2025-01-29 | DMAA | Drugs Made In America Acquisition Corp. | Stockwell Lynn | CEO, Exec COB, 10% | S - Sale+OE | $0.00 | -5,698,363 | 4,158,780 | -58% | -$0 | |||||
| A | 2025-01-31 | SYK | Stryker Corp | Stryker Ronda E | Dir, 10% | S - Sale | $392.75 | -236,000 | 3,607,467 | -6% | -$92,688,579 | |||||
2025-01-31 | MBWM | Mercantile Bank Corp | Williams Shoran R | Dir | P - Purchase | $49.28 | +123 | 4,147 | +3% | +$6,061 | ||||||
| M | 2025-01-31 | SMC | Summit Midstream Corp | Deneke J Heath | COB, Pres, CEO | S - Sale | $41.62 | -3,000 | 258,326 | -1% | -$124,860 | |||||
| D | 2025-02-03 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale+OE | $86.22 | -8,000 | 205,695 | -4% | -$689,790 | |||||
| M | 2025-01-31 | OCUL | Ocular Therapeutix, Inc | Notman Donald | See Remarks | S - Sale | $7.82 | -17,420 | 193,444 | -8% | -$136,239 | |||||
2025-01-31 | LICY | Li-Cycle Holdings Corp. | Kochhar Ajay | Pres, CEO, 10% | S - Sale | $1.02 | -1,266 | 3,269,133 | 0% | -$1,285 | ||||||
2025-01-31 | LICY | Li-Cycle Holdings Corp. | Biederman Christopher J. | CTO | S - Sale | $1.02 | -326 | 89,750 | 0% | -$331 | ||||||
2025-01-31 | LICY | Li-Cycle Holdings Corp. | Deluca Carl | See Remarks | S - Sale | $1.02 | -391 | 100,441 | 0% | -$397 | ||||||
2025-01-31 | LICY | Li-Cycle Holdings Corp. | Li Dawei | Chief Commercial Officer | S - Sale | $1.02 | -180 | 62,199 | 0% | -$183 | ||||||
| D | 2025-02-03 | BSX | Boston Scientific Corp | Butcher Arthur C | EVP,Grp Pres, MedSurg, APAC | S - Sale+OE | $101.80 | -17,313 | 18,866 | -48% | -$1,762,507 | |||||
| M | 2025-02-03 | SEMR | Semrush Holdings, Inc. | Levin Eugenie | Pres | S - Sale | $17.14 | -16,240 | 492,309 | -3% | -$278,314 | |||||
2025-01-31 | AMTB | Amerant Bancorp Inc. | Levine Howard A. | See remarks | S - Sale | $23.04 | -3,628 | 3,523 | -51% | -$83,580 | ||||||
2025-02-03 | ATEC | Alphatec Holdings, Inc. | Sponsel David | EVP, Sales | S - Sale | $11.42 | -36,256 | 735,074 | -5% | -$414,044 | ||||||
| D | 2025-02-03 | SNOW | Snowflake Inc. | Degnan Christopher William | Chief Revenue Officer | S - Sale+OE | $181.87 | -12,782 | 768,316 | -2% | -$2,324,695 | |||||
| D | 2025-02-03 | AI | C3.Ai, Inc. | Levin Richard C | Dir | S - Sale+OE | $29.84 | -12,000 | 161,664 | -7% | -$358,080 | |||||
| D | 2025-02-03 | AAPL | Apple Inc. | Levinson Arthur D | Dir | S - Sale+OE | $226.35 | -1,516 | 4,215,576 | 0% | -$343,147 | |||||
2025-02-03 | TEAM | Atlassian Corp | Cannon-Brookes Michael | CEO, Co-Founder, 10% | S - Sale | $311.20 | -7,948 | 309,972 | -3% | -$2,473,404 | ||||||
2025-02-03 | TEAM | Atlassian Corp | Farquhar Scott | Dir, 10% | S - Sale | $311.20 | -7,948 | 309,972 | -3% | -$2,473,403 | ||||||
2025-02-03 | SEMR | Semrush Holdings, Inc. | Mason David W | GC | S - Sale | $17.15 | -1,875 | 158,415 | -1% | -$32,156 | ||||||
| M | 2025-01-31 | DMLP | Dorchester Minerals, L.P. | Dorchester Minerals Operating LP | Entity Under Common Control | P - Purchase | $31.32 | +14,000 | 47,682 | +42% | +$438,525 | |||||
2025-02-03 | TER | Teradyne, Inc | Johnson Mercedes | Dir | S - Sale | $112.58 | -625 | 13,393 | -4% | -$70,363 | ||||||
| D | 2025-02-04 | ATYR | Atyr Pharma Inc | Broadfoot Jill Marie | CFO | S - Sale+OE | $3.78 | -1,254 | 31,763 | -4% | -$4,740 | |||||
2025-02-03 | CIEN | Ciena Corp | Smith Gary B | Pres, CEO | S - Sale | $84.86 | -6,800 | 412,149 | -2% | -$577,071 | ||||||
| M | 2025-01-31 | CUBI | Customers Bancorp, Inc. | Sidhu Jay S | COB, CEO | S - Sale | $56.96 | -100,173 | 1,523,361 | -6% | -$5,705,984 | |||||
| D | 2025-02-04 | ATYR | Atyr Pharma Inc | Denyes Nancy | GC | S - Sale+OE | $3.78 | -899 | 26,555 | -3% | -$3,398 | |||||
| D | 2025-02-03 | V | Visa Inc. | Rottenberg Julie B | GC | S - Sale+OE | $340.00 | -2,572 | 11,925 | -18% | -$874,480 | |||||
| D | 2025-01-31 | OTIS | Otis Worldwide Corp | Zheng Peiming | EVP, Chief Product, Delivery | S - Sale+OE | $95.43 | -32,694 | 169 | -99% | -$3,119,866 | |||||
| M | 2025-01-31 | PNRG | Primeenergy Resources Corp | De Rothschild Robert | 10% | S - Sale | $218.75 | -3,768 | 253,000 | -1% | -$824,266 | |||||
| D | 2025-02-03 | V | Visa Inc. | McInerney Ryan | CEO | S - Sale+OE | $340.00 | -8,620 | 247,326 | -3% | -$2,930,800 | |||||
2025-02-03 | HALO | Halozyme Therapeutics, Inc. | Henderson Jeffrey William | Dir | S - Sale | $56.30 | -5,000 | 38,611 | -11% | -$281,517 | ||||||
| D | 2025-01-31 | NBIX | Neurocrine Biosciences Inc | Cooke Julie | CHRO | S - Sale+OE | $152.89 | -1,740 | 18,202 | -9% | -$266,025 | |||||
2025-02-03 | AFRM | Affirm Holdings, Inc. | Rabois Keith | Dir | S - Sale | $60.12 | -16,086 | 77,608 | -17% | -$967,012 | ||||||
2025-02-03 | PETS | Petmed Express Inc | Nina Capital Holdings Inc. | 10% | P - Purchase | $4.82 | +25,000 | 2,250,000 | +1% | +$120,500 | ||||||
2025-02-03 | GMGI | Golden Matrix Group, Inc. | Milovanovic Aleksandar | Member of 10% Reporting Group, 10% | P - Purchase | $1.80 | +50,000 | 77,834,303 | 0% | +$90,000 | ||||||
| D | 2025-01-31 | NBIX | Neurocrine Biosciences Inc | Gorman Kevin Charles | Dir | S - Sale+OE | $152.93 | -2,707 | 517,030 | -1% | -$413,967 | |||||
| D | 2025-01-31 | NBIX | Neurocrine Biosciences Inc | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $152.81 | -1,457 | 32,373 | -4% | -$222,636 | |||||
| D | 2025-02-03 | AKBA | Akebia Therapeutics, Inc. | Butler John P. | CEO, Pres | S - Sale+OE | $2.10 | -144,250 | 2,924,186 | -5% | -$302,925 | |||||
2025-02-03 | SYBX | Synlogic, Inc. | Dooley Mary Beth | See Remarks below | S - Sale | $1.33 | -2,107 | 13,045 | -14% | -$2,802 | ||||||
| D | 2025-02-03 | AKBA | Akebia Therapeutics, Inc. | Burke Steven Keith | SVP, Chief Medical Officer | S - Sale+OE | $2.10 | -50,506 | 816,234 | -6% | -$106,063 | |||||
2025-02-03 | CRM | Salesforce, Inc. | Reddy Sundeep G. | EVP, Chief Accounting Officer | S - Sale | $335.94 | -500 | 6,557 | -7% | -$167,970 | ||||||
| D | 2025-02-03 | AKBA | Akebia Therapeutics, Inc. | Malabre Richard C | SVP, Chief Accounting Officer | S - Sale+OE | $2.10 | -30,202 | 280,248 | -10% | -$63,424 | |||||
| D | 2025-02-03 | AKBA | Akebia Therapeutics, Inc. | Grund Nicholas | Chief Commercial Officer | S - Sale+OE | $2.10 | -55,621 | 442,579 | -11% | -$116,804 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |